Clinical

Dataset Information

0

Clinical study to examine the effectiveness of Juzentaihoto in postoperative recovery for colorectal cancer patients - A research investigating the role of cell-mediated immunity in recovery


ABSTRACT: Interventions: Juzentaihoto is administered orally 7.5g/day in 2-3 dosages, before or between meals Total duration of test: 24 weeks starting from one week after surgery Juzentaihoto is not administered. Primary outcome(s): 1.ECOG’s Performance Status (ECOG=Eastern Cooperative Oncology Group) 2.Weight 3.QOL-ACD (The QOL Questionnaire for Cancer Patients Treated with Anticancer Drugs) 4.Hematological test (RBC, Hb, Ht, WBC, differential leukocyte count, PLT) 5.Serum albumin 6.Cell-mediated immunity (HLA-DR/CD3, CD11b/CD8, NK-cell activity) 7.Blood cytokine (IL-6, IL-10, IL-12, IL-18, TGF-beta, IFN-gamma) 8.Carcinoembryonic antigen (CEA) 9.Recurrence of cancer 10.Metastasis of cancer 11.Duration of anticancer drug therapy Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2616728 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2022-02-17 | PXD024385 | Pride
| PRJNA163105 | ENA
2024-02-14 | PXD048453 | Pride
2010-06-24 | E-GEOD-20084 | biostudies-arrayexpress
| 2702233 | ecrin-mdr-crc
2013-12-31 | E-GEOD-45458 | biostudies-arrayexpress
| 2623343 | ecrin-mdr-crc
| PRJNA288800 | ENA
| PRJNA135763 | ENA
2009-04-04 | E-GEOD-15536 | biostudies-arrayexpress